222 reports of this reaction
1.9% of all KETOTIFEN FUMARATE reports
#5 most reported adverse reaction
OCULAR HYPERAEMIA is the #5 most commonly reported adverse reaction for KETOTIFEN FUMARATE, manufactured by Alcon Laboratories, Inc.. There are 222 FDA adverse event reports linking KETOTIFEN FUMARATE to OCULAR HYPERAEMIA. This represents approximately 1.9% of all 11,458 adverse event reports for this drug.
Patients taking KETOTIFEN FUMARATE who experience ocular hyperaemia should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
OCULAR HYPERAEMIA is a less commonly reported adverse event for KETOTIFEN FUMARATE, but still significant enough to appear in the safety profile.
In addition to ocular hyperaemia, the following adverse reactions have been reported for KETOTIFEN FUMARATE:
The following drugs have also been linked to ocular hyperaemia in FDA adverse event reports:
OCULAR HYPERAEMIA has been reported as an adverse event in 222 FDA reports for KETOTIFEN FUMARATE. This does not prove causation, but indicates an association observed in post-market surveillance data.
OCULAR HYPERAEMIA accounts for approximately 1.9% of all adverse event reports for KETOTIFEN FUMARATE, making it a notable side effect.
If you experience ocular hyperaemia while taking KETOTIFEN FUMARATE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.